Selank

Yes, Selank is a synthetic heptapeptide (a peptide composed of seven amino acids) developed in Russia as a nootropic and anxiolytic medication. It is designed to act as an analog of the natural human peptide tuftsin (Thr-Lys-Pro-Arg-Pro-Gly-Pro).

Key Benefits

• May support stress reduction and a calmer mental state
• Commonly researched for improving focus, memory, and cognitive performance
• May help support mood balance without significant sedative effects
• Research suggests potential benefits for anxiety support and mental resilience

FDA-Approved Uses

It is an approved prescription drug in Russia for anxiety and stress-related disorders.

Regulatory status (as of May 2026)

• Previously: FDA Category 2 (compounding prohibited)
• April 22, 2026: Removed from Category 2 following HHS Secretary directive
• Standard 503A/503B pharmacy regulations now apply — formal rulemaking not yet complete
• PCAC review scheduled July 23, 2026 at FDA White Oak Campus
• Does NOT constitute FDA approval. Selank remains unapproved for any US therapeutic use.

Russian-approved indications (not valid in USA)

1. Generalized anxiety disorder
2. Neurasthenia (stress-related fatigue/exhaustion)
3. Asthenic conditions (weakness, fatigue)

Conditions studied in research / off-label use worldwide

• Anxiety and stress management
• Depression (mild to moderate)
• PTSD (as adjunct; off-label)
• Cognitive enhancement (focus, memory)
• Immunomodulation (stimulates immune function; based on tuftsin origin)
• Alcohol and substance dependency (adjunctive; limited data)
• Benzodiazepine tapering support (Russia — clinical use reported)

Trade Names in the USA and Manufacturers

Russian pharmaceutical brand:
– Selank 0.15% nasal spray solution — developed by Institute of Molecular Genetics (IMG), Russian Academy of Sciences, Moscow
(Same institute that developed Semax)

US availability of Selank

• As of April 22, 2026: Available via licensed 503A compounding pharmacies with valid physician prescription (Category 2 removal). Formal FDA rulemaking pending — verify current legal status before dispensing.
• Grey-market online vendors (unregulated): Available internationally
• Russian pharmaceutical nasal spray: Accessible through specialty importers

Molecular identity:

• Synthetic heptapeptide (7 amino acids): Thr-Lys-Pro-Arg-Pro-Gly-Pro
• Derived from: Tuftsin (Thr-Lys-Pro-Arg), a naturally occurring immunomodulatory tetrapeptide
• Additional Pro-Gly-Pro sequence added to increase stability and duration of action
• MW: ~863 Daltons

Dosage

Intranasal spray (most common and preferred route):

• Standard dose: 250–3,000 mcg/day
• Russian clinical: 400–900 mcg/day (0.15% solution, 2–3 drops per nostril, 1–3x daily)
• Typical off-label: 250–750 mcg/day starting dose
• Anxiolytic range: 250–500 mcg/day (lower doses for anxiety)
• Nootropic range: 750–1,000 mcg/day

Subcutaneous injection (off-label):
100–300 mcg once daily or twice daily

Cycling protocols:
Russian clinical: 10–14 day courses; repeated as needed
Off-label Western use: 10–14 days on, 1–2 week break
Some use: 5 days on / 2 days off
[Cycling reduces tolerance development]

Form availability:
– 0.15% nasal spray (Russian pharmaceutical)
– Lyophilized powder for injection (compounded)
– Transdermal patches (experimental; not widely used)

Combination use:
Sometimes combined with Semax for synergistic cognitive + anxiolytic effects

Pricing

No FDA-approved commercial pricing.

Russian pharmaceutical nasal drops (imported):
~$20–$50 per bottle (0.15% solution, 3 mL)
Monthly cost: ~$30–$80/month

Compounded Selank (503A pharmacy, where legally available with prescription):
~$80–$180/month depending on pharmacy and dose

Research peptide vendors (unregulated):
~$25–$60 per vial or bottle

Note: Selank is generally slightly cheaper than Semax due to less complex synthesis.

Coverage by Insurance Type

If PCAC review (July 23, 2026) results in Category 1 classification, licensed 503A compounding pharmacy access will be available with prescription — but insurance coverage for compounded peptides is rare even when legally available.

Tips

• Monitor July 23, 2026 PCAC review outcome for Selank specifically.
• Selank has a fundamentally different mechanism from benzodiazepines (Valium, Xanax) — it modulates GABA-A receptors in a way that reduces anxiety WITHOUT significant sedation and without physical dependence or withdrawal syndrome.
• Some Russian clinicians use Selank to assist benzodiazepine tapering — the anxiolytic support can ease withdrawal.
• Selank is a good candidate for patients who need anxiety management without cognitive impairment (it is not sedating at standard doses and may improve cognition concurrently).
• Unlike Semax (primarily cognitive/stimulant), Selank’s primary effect is anxiolytic at lower doses and cognitively enhancing at higher doses.
• Not WADA-prohibited — this is a meaningful advantage for athletes who need anxiety management.

Side Effects

From Russian clinical literature and off-label reporting (limited independent Western studies):

Mild and uncommonly reported:
– Nasal irritation / mild discomfort with intranasal use (uncommon; milder than Semax per comparative reports)
– Mild drowsiness or sedation at higher doses (uncommon; significantly less than benzodiazepines)
– Mild headache (transient)
– Lightheadedness or dizziness (uncommon)

Positive ‘side effects’ (reported as benefits by most users):
– Anxiolytic effect: Reduces anxiety and stress without sedation
– Mild mood elevation
– Improved focus and concentration

Distinctive safety profile compared to benzodiazepines:
– No physical dependence or withdrawal syndrome reported in clinical data
– No significant respiratory depression
– No cognitive impairment (contrast with benzodiazepine sedation)
– No tolerance requiring dose escalation in short-course treatment

Overall:
– Russian clinical data spanning decades reports a favorable side effect profile
– ADDF (Alzheimer’s Drug Discovery Foundation) report: ‘Very little human evidence for potential side effects’ — presumed low based on published data and clinical use
– Independent Western long-term safety data is very limited

Key caveat: Long-term safety, drug interactions, and population-specific risks have not been characterized in large Western clinical trials.

Contraindications

No formal FDA contraindications (no approved US label).

Based on Russian prescribing information and pharmacology:
– Known hypersensitivity to Selank or its components: Avoid
– Pregnancy and breastfeeding: Insufficient safety data; not recommended
– Children: Limited data; not established as safe in pediatric population
– Severe hepatic or renal impairment: Not characterized; use with caution
– Combined use with benzodiazepines: Theoretical additive GABAergic effects — may enhance sedation; use with caution; however, also used clinically in Russia to facilitate benzo tapering under supervision
– Combined use with CNS depressants (alcohol, opioids, sedating antihistamines): Additive sedation possible at higher Selank doses
– Psychosis or active manic episode: GABA modulation may interact unpredictably — use with caution under physician supervision

Pharmacology

Selank (Thr-Lys-Pro-Arg-Pro-Gly-Pro) is a synthetic heptapeptide (7 amino acids) and structural analogue of tuftsin (Thr-Lys-Pro-Arg), a naturally occurring tetrapeptide produced by cleavage of immunoglobulin G. It was developed at the Institute of Molecular Genetics, Russian Academy of Sciences (the same group that developed Semax). The additional Pro-Gly-Pro C-terminal sequence was added to increase resistance to proteolytic degradation and extend biological activity vs. native tuftsin (which has a very short half-life). MW: ~863 Daltons. Available as: 0.15% nasal spray solution (preferred route; nasal-olfactory direct CNS delivery pathway), lyophilized powder for reconstitution (injectable), and compounded formulations. Unlike Semax (ACTH-derived, primarily neurotrophin-modulating), Selank’s origin from tuftsin gives it dual neuropsychiatric and immunomodulatory properties — reflecting tuftsin’s natural role as a phagocytosis-activating immunopeptide.

Mechanism of action

Selank exerts effects through multiple neuropsychiatric and immunological pathways:

1. GABA-A Receptor Modulation (primary anxiolytic mechanism):
Selank modulates GABA-A receptor function in a manner similar to but distinct from benzodiazepines.
Unlike benzodiazepines, Selank’s GABAergic modulation:
– Does not cause significant sedation at therapeutic doses
– Does not produce physical dependence or tolerance
– Does not cause respiratory depression
This is considered the basis for its anxiolytic effects without the benzodiazepine side effect burden.

2. BDNF Upregulation:
Like Semax, Selank increases BDNF expression — contributing to cognitive enhancement, neuroplasticity, and neuroprotective effects.

3. Enkephalin-Degrading Enzyme Inhibition:
Selank inhibits enzymes that break down Met-enkephalin and Leu-enkephalin (endogenous opioid peptides) — prolonging their anxiolytic and mood-stabilizing activity. This is considered a secondary anxiolytic mechanism.

4. Serotonin System Modulation:
Modulates serotonin turnover in limbic regions — contributing to mood stabilization and anxiety reduction.

5. Immunomodulation (derived from tuftsin origin):
Activates macrophage function and stimulates interleukin-2 (IL-2) and interferon synthesis
Enhances phagocytosis and natural killer cell activity
May be relevant in immune-compromised patients or during infection/stress.

6. Nootropic effects:
At higher doses, Selank improves attention, memory consolidation, and executive function — possibly via BDNF and serotonin mechanisms.

Result Claims from Different Companies

Russian Institute of Molecular Genetics / Russian pharmaceutical clinical data:

Anxiety and neurasthenia (Russian clinical trials):
– Multiple Russian RCTs demonstrate statistically significant anxiolytic effects vs. placebo in generalized anxiety disorder and neurasthenia
– Comparable efficacy to benzodiazepines (e.g., medazepam) on anxiety rating scales (Hamilton Anxiety Scale, STAI) in some trials
– Superior side effect profile: No sedation, no dependence, no withdrawal syndrome vs. comparator benzodiazepines
– Reported improvement in cognitive function alongside anxiety reduction (contrast with benzodiazepines which impair cognition)

Immune function (Russian literature):
– Demonstrated activation of macrophage function and cytokine production in both in vitro and in vivo studies

ADDF (Alzheimer’s Drug Discovery Foundation) Cognitive Vitality Report:
– Acknowledged anxiolytic and potential cognitive benefits based on Russian data
– Noted significant limitations: almost all data from Russian studies; lack of independent Western RCT validation
– Concluded evidence insufficient for widespread Western clinical recommendation without further trials

Psychiatrist Dr. Baghel (US clinical perspective, 2026):
– Describes Selank as adjunctive in anxiety and PTSD management alongside evidence-based psychotherapy (CPT, prolonged exposure, EMDR)
– Notes: ‘Neither Semax nor Selank is FDA-approved. The available safety data from Russian clinical use spanning decades shows a favorable side effect profile.’

⚠️ The majority of clinical evidence originates from Russian institutions with limited independent replication. No Phase 3 data reviewed by the FDA exists for any indication.

Disclaimer

This content about “Selank” is for informational and educational purposes only, is not medical advice, does not replace consultation with a licensed healthcare professional, and affiliate links may result in compensation at no additional cost to you.